Magnetic Nanoparticles for Targeted Drug Delivery in a Mouse Model of Breast Cancer
نویسندگان
1 Docent Department of Anatomy with Physiology Courses, Kazakh-Russian Medical University, Almaty, Kazakhstan
2 Termez State University, Termez, Uzbekistan
3 Department of Physics of the Navoi state pedagogical institute, Navoi, Uzbekistan
4 Termez State University, Termez, Uzbekistan
5 Tashkent Institute of Irrigation and Agricultural Mechanization Engineers, National Research University, Tashkent, Uzbekistan
6 Department of Fruits and Vegetables, Urganch State University, Uzbekistan
7 Department of Rehabilitation, Folk Medicine and Physical Education, Tashkent Medical Academy, Tashkent, Uzbekistan
8 Departement of Biology, Universitas Islam Malang, Indonesia
9 Department of Oncology of the Andijan State Medical Institute, Andijan, Uzbekistan
10 Termez State University, Termez, Uzbekistan
11 University of Tashkent for Applied Sciences, Tashkent, Uzbekistan
12 Western Caspian University, Scientific researcher, Baku, Azerbaijan
13 Department Clinic Pharmacology, Bukhara State Medical University, Uzbekistan
doi
10.22052/JNS.2024.01.010چکیده
Targeted drug delivery using magnetic nanoparticles (MNPs) has emerged as a promising approach for cancer therapy. This study investigates the efficacy of MNPs for targeted delivery of doxorubicin (DOX) in a mouse model of breast cancer. MNPs were synthesized by co-precipitation and functionalized with DOX. The MNP-DOX conjugates were characterized using TEM, XRD, and FTIR. Female BALB/c mice (n=24) were inoculated with 4T1 breast cancer cells. The mice were divided into four groups: control, DOX, MNP, and MNP-DOX. Every 3 days over a 2-week period, intravenous administration of treatments occurred. Monitoring of tumor volume and body weight took place. Histological analysis and immunohistochemical staining for Ki-67 and caspase-3 were performed on tumor tissues. MNP-DOX conjugates were successfully synthesized and characterized, showing effective drug loading and release. Tumor growth was significantly inhibited in the MNP-DOX group compared to the control, DOX, and MNP groups. The MNP-DOX group exhibited the smallest tumor volume (135±28 mm³) at the end of the treatment period. Histological analysis revealed increased necrosis and apoptosis in the MNP-DOX group. Immunohistochemical staining showed reduced Ki-67 expression and increased caspase-3 expression in the MNP-DOX group. MNPs functionalized with DOX demonstrated effective targeted drug delivery and enhanced therapeutic efficacy in a mouse model of breast cancer. The MNP-DOX conjugates significantly inhibited tumor growth, increased necrosis and apoptosis, and modulated Ki-67 and caspase-3 expression. These findings support the potential of MNPs as a promising platform for targeted cancer therapy. Further studies are needed to optimize the MNP formulation and assess its safety and efficacy in clinical settings.
